1985
DOI: 10.1097/00004728-198503000-00003
|View full text |Cite
|
Sign up to set email alerts
|

Gadolinium-DTPA as a Contrast Agent in MR Imaging—Theoretical Projections and Practical Observations

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
48
0

Year Published

1992
1992
2005
2005

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 138 publications
(49 citation statements)
references
References 0 publications
1
48
0
Order By: Relevance
“…The effects of paramagnetic contrast agents (i.e., gadolinium-DTPA) in MRI are well known (11). The two main characteristics that affect their MR performance are 1) the concentration of the paramagnetic contrast agent that reaches the tissue being studied, and 2) the tissue relaxation rate changes caused by the paramagnetic agent (11).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The effects of paramagnetic contrast agents (i.e., gadolinium-DTPA) in MRI are well known (11). The two main characteristics that affect their MR performance are 1) the concentration of the paramagnetic contrast agent that reaches the tissue being studied, and 2) the tissue relaxation rate changes caused by the paramagnetic agent (11).…”
Section: Discussionmentioning
confidence: 99%
“…The two main characteristics that affect their MR performance are 1) the concentration of the paramagnetic contrast agent that reaches the tissue being studied, and 2) the tissue relaxation rate changes caused by the paramagnetic agent (11). Given these characteristics and the relationships between the relaxation times of the tissues and the parameters of the MR pulse sequence, it is possible to calculate how a contrast agent will change the MR signal intensity of a particular tissue.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…For the Gd-DTPA, 54% was released by day 1, 0.2%/day was released during the slow steady-state phase (days 2-16), and 5%/day was released during the rapid steady-state phase (days 18 -24). For the VEGF, 3% was released by day 1, 0.1%/day was released during the slow steady-state phase (days [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20], and 6%/day was released during the rapid steady-state phase (days 24 -35). The release of VEGF slightly lags that of Gd-DTPA.…”
Section: Release Kineticsmentioning
confidence: 99%
“…Six dif ferentTI and T2 relaxationtimes were used in the simulationof enhancingbrain lesionsto accountfor (2) vanabilityin lesionvasculantyand degreeof blood brain barrier disruption as well as for gadolinium dosing and image timing considerations. The con centration of gadolinium in the simulated lesions was varied from 0.58 to 4.75 mmol/l with the as sumption that the enhancing lesion relaxation rates (Ti@dand thi@) varied linearlywith the con centrationof gadolinium [7,8]. The six differentTl andT2 relaxation times were calculatedfor six differ ent gadoliniumconcentrations [9].…”
Section: Other Investigators Have Advocatedgadolin Ium-enhanced Fast mentioning
confidence: 99%